ASX:TLXBiotechs
How Regeneron Tie-Up And Phase 3 Pipeline Advances At Telix Pharmaceuticals (ASX:TLX) Has Changed Its Investment Story
Telix Pharmaceuticals recently announced several milestones, including the first patient dosed in the pivotal Phase 3 IPAX BrIGHT trial of TLX101-Tx for recurrent glioblastoma and the upcoming presentation of Phase 3 safety data for its prostate cancer therapy TLX591-Tx at the 2026 ASCO Annual Meeting.
In parallel, Regeneron Pharmaceuticals and Telix entered a broad collaboration pairing Regeneron’s antibody portfolio with Telix’s radiopharmaceutical platform, potentially expanding Telix’s...